Veterinary News and Research

RSS

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

Pulmonary hypertension is an umbrella term used for many conditions that all result in elevation of the pulmonary arterial pressure. Of interest, many of these completely different clinical and pathophysiological entities result in a final common pathway of vasoconstriction, micro thrombosis and vascular remodelling.

10 Dec 2015

FDA clears for marketing first cooling cap to reduce chemotherapy-induced hair loss

Today, the U.S. Food and Drug Administration cleared for marketing in the United States the first cooling cap to reduce hair loss (alopecia) in female breast cancer patients undergoing chemotherapy.

9 Dec 2015

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD.

8 Dec 2015

Kanuma approved as first treatment for patients with LAL deficiency

Today, the U.S. Food and Drug Administration approved Kanuma (sebelipase alfa) as the first treatment for patients with a rare disease known as lysosomal acid lipase (LAL) deficiency.

8 Dec 2015

Plasmacytoid dendritic cells may not contribute to late-stage lupus

For years, biomedical researchers have suspected that a specific set of immune cells are responsible for causing disease in lupus patients, but until now they haven't known for sure one way or the other.

8 Dec 2015

FDA clears use of XSTAT 30 wound dressing to control severe bleeding in civilian population

Today, the U.S. Food and Drug Administration cleared the use of the XSTAT 30 wound dressing, an expandable, multi-sponge dressing used to control severe, life-threatening bleeding from wounds in areas that a tourniquet cannot be placed (such as the groin or armpit) in battlefield and civilian trauma settings.

8 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

University of Georgia researchers evaluate potential new strategy to combat drug-resistant diseases

Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.

26 Nov 2015

Researchers aiming to improve accuracy of current diagnostics for Leishmania infantum kinetoplast

In an article published in Small, researchers successfully applied a new qualitative and quantitative method for the detection of a DNA sequence characteristic of Leishmania infantum kinetoplast, a frequent parasite in veterinary that affects humans too.

26 Nov 2015

First seasonal influenza vaccine containing adjuvant now approved by FDA

The U.S. Food and Drug Administration today approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older.

25 Nov 2015

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

The U.S. Food and Drug Administration today approved Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) who have not previously received medication specifically for treating their advanced lung cancer.

24 Nov 2015

BioThrax approved to prevent disease after exposure to anthrax spores

The U.S. Food and Drug Administration today approved a new indication for BioThrax (Anthrax Vaccine Adsorbed) to prevent disease following suspected or confirmed exposure to Bacillus anthracis, the bacterium that causes anthrax disease. The vaccine's new use is approved for people 18 through 65 years of age in conjunction with recommended antibiotic treatment. BioThrax was initially approved by the FDA in 1970 for the prevention of anthrax disease in persons at high risk of exposure.

24 Nov 2015

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.

23 Nov 2015

Prevalence of antimicrobial resistance in horses, other companion animals may impact human health

Bacterial resistance to antimicrobial agents is a significant problem for both human and veterinary medicine, but little research has been done on the prevalence or mechanisms of resistance in horses and other companion animals, and how such resistance might impact human health.

23 Nov 2015

Ninlaro (ixazomib) approved to treat people with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Ninlaro (ixazomib) in combination with two other therapies to treat people with multiple myeloma who have received at least one prior therapy.

21 Nov 2015

FDA takes important steps regarding genetically engineered plants and animals intended for food

Based on sound science and a comprehensive review, the U.S. Food and Drug Administration is taking several important steps today regarding food from genetically engineered (GE) plants and animals, including the first approval for a genetically engineered animal intended for food, AquAdvantage Salmon.

20 Nov 2015

Scientists identify way to sensitize drug-resistant glioblastoma cells to chemotherapy

Scientists from the Virginia Tech Carilion Research Institute and clinicians from Carilion Clinic have discovered how to sensitize drug-resistant human glioblastoma cells to chemotherapy.

20 Nov 2015

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

Today the U.S. Food and Drug Administration approved Narcan nasal spray, the first FDA-approved nasal spray version of naloxone hydrochloride, a life-saving medication that can stop or reverse the effects of an opioid overdose. Opioids are a class of drugs that include prescription medications such as oxycodone, hydrocodone, and morphine, as well as the illegal drug heroin.

18 Nov 2015

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma.

17 Nov 2015

FDA finalizes innovative food safety rules to prevent foodborne illness

The U.S. Food and Drug Administration today took major steps to prevent foodborne illness by finalizing rules implementing the bipartisan Food Safety Modernization Act that, for the first time, establish enforceable safety standards for produce farms and make importers accountable for verifying that imported food meets U.S. safety standards.

15 Nov 2015

Veterinary News and Research

Study reveals pathogenetic role of miR-125a in pulmonary hypertension

FDA clears for marketing first cooling cap to reduce chemotherapy-induced hair loss

FDA approves recombinant von Willebrand factor for treating bleeding episodes in adults with VWD

Kanuma approved as first treatment for patients with LAL deficiency

Plasmacytoid dendritic cells may not contribute to late-stage lupus

FDA clears use of XSTAT 30 wound dressing to control severe bleeding in civilian population

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

University of Georgia researchers evaluate potential new strategy to combat drug-resistant diseases

Researchers aiming to improve accuracy of current diagnostics for Leishmania infantum kinetoplast

First seasonal influenza vaccine containing adjuvant now approved by FDA

Portrazza approved to treat patients with advanced squamous non-small cell lung cancer

BioThrax approved to prevent disease after exposure to anthrax spores

Opdivo (nivolumab) approved to treat patients with advanced renal cell carcinoma

Prevalence of antimicrobial resistance in horses, other companion animals may impact human health

Ninlaro (ixazomib) approved to treat people with multiple myeloma

FDA takes important steps regarding genetically engineered plants and animals intended for food

Scientists identify way to sensitize drug-resistant glioblastoma cells to chemotherapy

FDA approves Narcan nasal spray to prevent or reverse effects of opioid overdose

FDA grants accelerated approval for Darzalex to treat patients with multiple myeloma

FDA finalizes innovative food safety rules to prevent foodborne illness

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News